[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100613479","phase-1-a-clinical-study-to-evaluate-the-safety-tolerability-and-pharmacokinetic-profile-of-tqc3302-inhalation-spray-in-healthy-adult-subjects-100613479",false,"NCT07267130","A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects in China","Inclusion Criteria:\n\n* Subjects voluntarily joined the study, sign informed consent form before the study and fully understand the study content\n* Healthy subjects aged between 18 and 55 years (inclusive),both male and female\n* The male subject should weigh at least 50kg, the female subject should weigh at least 45kg. And body mass index (BMI) within 19\\~28 kg\u002Fm2\n* Inhalation administration training qualified.\n* During the screening period, the percentage of predicted value for forced expiratory volume in one second (FEV1) before bronchodilator administration is ≥80%, and FEV1\u002Fforced vital capacity (FVC) is ≥70%.\n* Have no pregnancy plan and voluntarily take effective contraception measures from time of screening to at least 90 days after the last dose (subjects and their partners)\n\nExclusion Criteria:\n\n* Individuals with a history of glaucoma, functional constipation, benign prostatic hyperplasia, urinary tract obstruction, etc\n* Current history of active tuberculosis, bronchiectasis or other non-specific lung diseases\n* People who have received or are planning to receive inactive or active vaccines during the 30 days prior to the screening period and the entire study period\n* Any history of drug allergies, Individuals with a specific history of allergies or allergies\n* Had undergone surgery within 1 month prior to screening period or expected to undergo surgery during the study period\n* People with special dietary requirements who cannot follow a standard diet;\n* People who have potential difficulty in blood collection, or have a history of halo needles or blood sickness；\n* History of drug or narcotics abuse or a positive result of urine drug test at screening\n* People who have abnormal and clinically significant results in vital signs, physical examination, laboratory tests, Chest radiograph and abdominal ultrasound during screening period\n* Subjects Positive for Any of Hepatitis B Virus Surface Antigen (HBsAg), Hepatitis C Virus Antibody (Anti-HCV), Human Immunodeficiency Virus Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP)\n* Pregnant or lactating women or those with positive blood pregnancy test results during the screening period",true,"ALL","18 Years","55 Years",{"count":21,"type":22},57,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Groups 1, 3, 4, 5 and 6 of this research team adopted a single-center, open-label design. Group 2 used a three-sequence, three-period crossover design, where participants in this dose group were randomly assigned to the three sequences in a 1:1:1 ratio to undergo three-period crossover administration. Healthy adult subjects were selected to use TQC3302 inhalation spray to evaluate the safety, tolerability, and pharmacokinetic characteristics of single and multiple inhalations of TQC3302 inhalation spray in healthy participants.",[28],"Chronic Obstructive Pulmonary Disease","RECRUITING","2026-03-08",{"date":32,"type":33},"2026-03-10","ACTUAL",{"date":35,"type":33},"2025-11-25",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":41},"100566013","phase-1-a-multicenter-open-label-phase-i-clinical-trial-evaluating-the-safety-and-pharmacokinetics-of-tqb2252-injection-in-subjects-with-advanced-malignant-tumors-100566013","NCT06649656","A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors","Inclusion Criteria:\n\n* The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;\n* 18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);\n* Electrocorticogram (ECOG) score ranges from 0 to 1 points;\n* Expected survival is greater than 12 weeks；\n* Confirmed to have at least one measurable lesion according to RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria；\n* Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment；\n* Women of childbearing age should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;\n* There are multiple factors that affect diseases related to intravenous injection and venous blood collection;\n* The adverse reactions of previous anti-tumor treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score of ≤ 1;\n* Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;\n* Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first administration;\n* An arterial\u002Fvenous thrombotic event occurred within 6 months prior to the first administration;\n* Active viral hepatitis with poor control;\n* Active syphilis infected individuals in need of treatment;\n* History of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia;\n* Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;\n* Diagnosed with immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy due to a history of hepatic encephalopathy;\n* Previously experienced grade 3 or higher adverse reactions related to immunotherapy;\n* Suffering from significant cardiovascular disease;\n* Active or uncontrolled severe infections;\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis;\n* History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;\n* Individuals with epilepsy who require treatment;\n* Previously received treatment with similar anti-lag3 drugs.","75 Years",{"count":50,"type":22},100,[25],"This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.",[54],"Advanced Cancers","NOT_YET_RECRUITING","2024-10-17",{"date":58,"type":33},"2024-10-21",{"date":60,"type":22},"2024-11",{"date":37,"type":22},{"name":39,"class":40},""]